A new vaccine breaks into the “battle for Corona” … what is it and how does it work?

A new vaccine has joined the battle against the emerging corona virus and its mutated strains, and it has some commonalities and differences from other vaccines.

According to “Sky News” reports, Britain has granted approval for the use of the “Novavax” vaccine, manufactured by a US company, and has requested 60 million doses of it.

This is the fourth vaccine approved by the Boris Johnson government, after the “Pfizer Bionic”, “Oxford AstraZeneca” and “Moderna” vaccines. While the first and second vaccines have already begun to be distributed, the third has only received the light green.

In Britain, 7.5 million people have received the vaccine so far, and the vaccination campaign is seen as the UK’s best hope for ending the pandemic that has killed more than 100,000 Britons.

As for the vaccine, “Novavax”, it had an effectiveness rate of 89 percent overall.

The results showed that it is 95.6 percent effective against the original strain of Corona virus that spreads in the world, and 86.6 percent against the new strain that was discovered in Great Britain during December 2020.

Studies conducted on the vaccine included more than 15,000 participants between the ages of 18 and 84, 27 percent of whom were over 65.

A study was conducted in 4,400 people in South Africa, including some volunteers with HIV “AIDS,” and the vaccine appears to be 60 percent effective in these people and overall, provides 49 percent protection.

The American company plans to make a special vaccine targeting the South African strain.

The “Novavax” vaccine differs from the “Pfizer Biontech” and “Moderna” vaccines, which use k messenger RNA, “mRNA”, as it uses an inactivated virus, specifically through a modified protein of the virus that causes the epidemic, With a plant component to generate a stronger immune response in the body, if you encounter viruses in the future, you will be ready for it.

People will receive the vaccine in two doses, 3 weeks apart, similar to most currently known vaccines.

The “Novavax” vaccine is priced at $ 16, which means it is cheaper than the “Pfizer Bionic” and “Moderna” vaccines, but more expensive than the “Oxford AstraZeneca” vaccine and does not require special refrigerators. to preserve it, which means it can be distributed more easily and less expensively.